President Donald Trump unveiled TrumpRx as a revolution.

Standing before cameras in February, he described the government-backed prescription discount platform as one of the most important healthcare achievements in decades—a bold answer to the crushing drug prices that have forced millions of Americans to choose between medicine, food and rent.

Nearly six months later, a new analysis has delivered a devastating reality check.

According to an NPR review of federal drug data, the discounts offered through TrumpRx cover fewer than 12 percent of the more than 800 brand-name medications produced by the pharmaceutical companies participating in the program.

That means almost nine out of every 10 eligible brand-name drugs are missing.

For patients who believed the president’s sweeping promises, the gap between the announcement and the actual program could feel enormous.

TrumpRx was launched as the centerpiece of the administration’s effort to lower prescription costs for Americans paying cash. The platform carries Trump’s name, promotes what it calls special presidential deals and directs patients toward discounted prices negotiated with major pharmaceutical companies.

The pitch was simple and politically powerful: bypass the complicated system, cut out inflated prices and give ordinary Americans access to medicines at dramatic discounts.

But NPR’s findings suggest that the companies involved are selecting only a narrow slice of their products for inclusion.

“The companies are offering deals on the products that they choose, not the universe of products that they offer,” Boston University health economist Rena Conti told NPR.

That distinction is now at the center of the controversy.

The program may offer real savings on some medications, but critics argue that Trump and the White House promoted it as something far broader—a transformation of the prescription drug market rather than a limited collection of manufacturer-selected discounts.

Some of the most widely used and medically important drugs are nowhere to be found.

Pfizer’s blood thinner Eliquis, prescribed to reduce the risk of strokes and dangerous blood clots, is reportedly absent.

So is Ibrance, a major breast cancer treatment.

Paxlovid, Pfizer’s antiviral treatment for COVID-19, is also excluded.

Merck’s Keytruda, a prominent cancer drug used in the treatment of multiple serious cancers, does not appear on the platform either.

For patients who depend on those medications, a heavily promoted government discount site offers no relief.

The omissions also undermine the emotional promise behind TrumpRx.

Prescription pricing is not an abstract policy debate for families facing cancer, heart disease or chronic illness. A missed dose can carry serious consequences. A monthly bill can determine whether someone follows a doctor’s instructions or begins rationing medicine.

When a president promotes a program as a historic breakthrough, vulnerable patients may reasonably expect that it includes the drugs they need most.

The analysis suggests that many will search the site and come away disappointed.

There is another problem: even some of the discounts featured on TrumpRx may not be the cheapest option available.

NPR highlighted Pfizer’s antidepressant Pristiq, which is listed on the platform at approximately $200. A generic version of the same medication may cost only $20 to $30 when purchased using a GoodRx coupon.

That creates an uncomfortable contradiction.

A patient attracted by the words “presidential deal” could potentially pay far more than someone who simply chooses the generic alternative through an existing commercial discount service.

TrumpRx has advertised more than $400 million in savings, but the White House reportedly did not provide NPR with information showing how many patients have actually used the platform.

Without usage figures, it is difficult to determine how many people received discounts, how large their individual savings were or whether the headline number reflects realistic purchases rather than theoretical price comparisons.

That lack of transparency has renewed skepticism that existed from the program’s launch.

Critics questioned how the administration calculated its promised savings and whether the comparisons were based on prices patients routinely paid or higher list prices that often do not reflect real-world transactions.

Drug pricing in the United States is notoriously confusing.

A medicine may have a high manufacturer list price, a lower price negotiated by an insurer, a separate pharmacy discount and an even cheaper generic alternative. A large advertised percentage reduction can sound dramatic while still leaving the patient with a price higher than other available options.

TrumpRx attempted to simplify that maze.

Instead, critics say, it may have added another layer of marketing.

Pfizer defended its participation, saying it offers savings of as much as 85 percent on more than 30 medicines and will continue making adjustments as the program develops.

That statement suggests TrumpRx could expand over time.

But nearly six months after launch, the platform’s limited reach is becoming politically significant.

The findings arrive as Trump’s wider healthcare agenda faces scrutiny and legal challenges, including disputes over Medicaid work requirements. They also come as the midterm elections approach and Republicans attempt to persuade voters that the administration has lowered everyday costs.

Prescription prices are among the most politically sensitive household expenses.

Unlike gasoline or groceries, medication is often impossible to avoid. Patients cannot simply stop buying cancer treatments, blood thinners or drugs prescribed for serious mental and physical health conditions.

That is why the promises surrounding TrumpRx mattered.

The president did not introduce it as a small pilot program or a modest discount directory. He presented it as a landmark achievement—a defining answer to one of America’s most painful healthcare failures.

The NPR analysis now raises a much harsher question.

Was TrumpRx designed to provide comprehensive relief to patients—or to create the appearance of a healthcare revolution while pharmaceutical companies quietly decided which drugs were included?

For some Americans, the platform may still produce meaningful savings.

For many others, the medicine they need will not be there at all.

And behind the giant promises, presidential branding and claims of hundreds of millions of dollars saved, one number may prove impossible to ignore:

Less than 12 percent.